New research finds that topical ferulic acid significantly improves skin lesions and barrier function in patients with ...

Dermatology drugmaker Journey Medical has trekked its Dr. Reddy’s Laboratories-partnered rosacea med across the FDA finish line as Emrosi. | The drug proved superiority in clearing lesions over ...

GlobalData is Pharmaceutical Technology’s parent company. Rosacea is a chronic inflammatory skin condition, which causes reddening of the skin, lesions and ‘spider veins’, usually around the nose and ...

Rosacea is a chronic inflammatory skin condition, which causes reddening of the skin, lesions and ‘spider veins’, usually around the nose and cheeks. Early symptoms may come and go ...

Journey Medical said on Monday the U.S. Food and Drug Administration has approved its drug for the treatment of a long-term ...

Journey Medical said on Monday the U.S. Food and Drug Administration has approved its drug for the treatment of a long-term ...

Opens in a new tab or window The FDA approved minocycline hydrochloride extended-release capsules (Emrosi) for treating ...

Cases of anaphylaxis, serious skin reactions, erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported in patients using minocycline ...

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder ... new oral treatment for the ...

The FDA is set to decide on four promising therapies in the next two weeks, including a CAR T for acute lymphoblastic ...

(RTTNews) - Journey Medical (DERM) announced the FDA has approved Emrosi for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's ...

make an appointment with a primary care provider or a dermatologist who specializes in dark skin to find the best treatment plan for you. You may also want to learn as much as you can about eczema to ...